Hence glucagon-like peptide 1 (GLP-1) therapy is now a well-established class in the treatment paradigm for type 2 diabetes (T2DM) given its glycaemic efficacy and weight loss potency as well as favourable cardiometabolic outcomes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.